Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

PTAB Institutes Samsung Bioepis IPR Against Regeneron’s Eylea® (aflibercept) Patent and Joins Celltrion IPR

Dec 8, 2023

The US Patent Trial and Appeal Board (PTAB) has instituted Samsung Bioepis’ inter partes review (IPR) petition challenging Regeneron’s Eylea® (aflibercept) patent no. 10,464,992 in IPR proceeding IPR2023-01312.  The patent claims formulations of aflibercept suitable for intravitreal injection.  Samsung Bioepis also successfully filed a Motion for Joinder requesting to join the proceeding with IPR2023-00462, in which PTAB instituted Celltrion’s IPR against the ‘992 patent.

On 18 August 2023 Samsung Bioepis filed an IPR petition against ‘992 and sought joinder with the Celltrion IPR filed against the same Regeneron patent on 17 January 2023.